Navidea biopharmaceuticals announces positive results encompassing additional patients from its ongoing phase 2b study in rheumatoid arthritis

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce positive results from analysis of subjects who have completed arm 3 of the company's ongoing nav3-31 phase 2b study. these data further corroborate navidea's hypotheses that tc99m tilmanocept imaging can provide robust, quantitative imaging in patients with acti
NAVB Ratings Summary
NAVB Quant Ranking